Facile and novel one-pot three-component synthesis of isatin-thiazoles catalyzed by biogenic iron oxide nanoparticles

Chandrappa, Anjan Kumar Ganadakatte; Bodke, Yadav Dasharath Rao; Obaih, Nagaraja; Hamzad, Shanavaz

doi:10.1016/j.cdc.2022.100964

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 3D structure of target protein Human Topo IIα ATPase/AMP‐PNP (PDB ID: 1ZXM) and carbonic anhydrase II in complex with pyrimidine‐based inhibitor (PDB ID: 6VJ3) was downloaded from the protein database (http://www.rcsb.org). [ 49 ] To create clean protein, the inhibitors, additional ligands, and water molecules were removed from the protein before it was prepared. Before docking, polar hydrogen atoms with Gasteiger–Huckel charges were added to the protein.…”

Section: Methodsmentioning

confidence: 99%

Imidazopyridine chalcones as potent anticancer agents: Synthesis, single‐crystal X‐ray, docking, DFT and SAR studies

Soumyashree,

Reddy,

Nagarajaiah

et al. 2023

Archiv der Pharmazie

View full text Add to dashboard Cite

New imidazopyridine–chalcone analogs were synthesized through the Claisen–Schmidt condensation reaction. The newly synthesized imidazopyridine‐chalcones (S1–S12) were characterized using spectroscopic and elemental analysis. The structures of compounds S2 and S5 were confirmed by X‐ray crystallography. The global chemical reactivity descriptor parameter was calculated using theoretically (DFT‐B3LYP‐3‐211, G) estimated highest occupied molecular orbital and lowest unoccupied molecular orbital values and the results are discussed. Compounds S1–S12 were screened on A‐549 (lung carcinoma epithelial cells) and MDA‐MB‐231 (M.D. Anderson‐Metastatic Breast 231) cancer cell lines. Compounds S6 and S12 displayed exceptional antiproliferative activity against lung A‐549 cancer cells with IC50 values of 4.22 and 6.89 µM, respectively, compared to the standard drug doxorubicin (IC50 = 3.79 μM). In the case of the MDA‐MB‐231 cell line, S1 and S6 exhibited exceptionally superior antiproliferative activity with IC50 of 5.22 and 6.50 μM, respectively, compared to doxorubicin (IC50 = 5.48 μM). S1 was found to be more active than doxorubicin. Compounds S1–S12 were tested for their cytotoxicity on human embryonic kidney 293 cells, which confirmed the nontoxic nature of the active compounds. Further molecular docking studies verified that compounds S1–S12 have a higher docking score and interacted well with the target protein. The most active compound S1 interacted well with the target protein carbonic anhydrase II in complex with pyrimidine‐based inhibitor, and S6 with human Topo IIα ATPase/AMP‐PNP. The results suggest that imidazopyridine‐chalcone analogs may serve as new leads as anticancer agents.

show abstract

Section: Methodsmentioning

confidence: 99%